MISSISSAUGA, Ontario, January 26, 2024--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced the following management changes.

Interim CFO Appointment and Transition

The Company will appoint Ms. Katie Martinovich as Interim Chief Financial Officer of Covalon. Ms. Martinovich will succeed Mr. Jason Gorel, who will be stepping down in February, 2024 to pursue other endeavours. Ms. Martinovich is currently Covalon's Vice President - Finance.

Appointment of Senior Vice President – Operations

Ms. Kim Crooks has rejoined Covalon as the Senior Vice President - Operations. In this new role, Ms. Crooks is responsible for overseeing the direction, planning, and execution of Manufacturing, Quality Assurance and Quality Control, Regulatory Affairs, and Human Resources. Ms. Crooks was previously Vice President of Operations at Covalon from 2012 to 2022.

Mr. Brent Ashton, Chief Executive Officer of Covalon Technologies Ltd., stated, "We would like to thank Mr. Gorel for his many contributions to Covalon and wish him well in his future. We are very glad to have both Ms. Martinovich and Ms. Crooks take on their new roles and join the Covalon executive leadership team to help us achieve our mission of providing innovative, gentler, and more compassionate options for patients to heal with less infections, less pain, and better outcomes."

About Covalon

Covalon Technologies Ltd. is a patient-driven medical device company, built on the relentless pursuit to help the most vulnerable patients have a better chance at healing. Through a strong portfolio of patented technologies and solutions for advanced wound care, infection prevention, and medical device coatings, we offer innovative, gentler, and more compassionate options for patients to heal with less infections, less pain, and better outcomes. Our solutions are designed for patients and made for care providers. Covalon leverages its patented medical technology platforms and expertise in two ways: (i) by developing products that are sold under Covalon’s name; and (ii) by developing and commercializing medical products for other medical companies under development and license contracts. The Company is listed on the TSX Venture Exchange, having the symbol COV and trades on the OTCQX Market under the symbol CVALF. To learn more about Covalon, visit our website at www.covalon.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.